{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:28:24Z","timestamp":1786429704643,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early neurological deterioration (END) is common after acute ischemic stroke and is associated with poor functional outcomes. Argatroban and tirofiban are increasingly used as rescue antithrombotic therapies for END, but their comparative effectiveness remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This two-center retrospective cohort study included patients with atherosclerosis-related acute ischemic stroke complicated by END who were treated with either argatroban or tirofiban. Propensity scores with stabilized inverse probability of treatment weighting (IPTW) and overlap weighting were applied to reduce confounding. The primary outcome was a favorable functional outcome at 90\u00a0days (modified Rankin Scale [mRS] score of 0\u20132). Secondary outcomes included excellent functional outcomes (mRS score of 0\u20131), mRS shift, neurological improvement, and safety outcomes. Subgroup and sensitivity analyses were also performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 139 patients were included (argatroban, n = 68; tirofiban, n = 71). After weighting, no statistically significant differences were observed in favorable functional outcomes at 90\u00a0days between argatroban and tirofiban in the stabilized IPTW analysis (RR, 0.80, 95% CI: 0.60\u20131.06) and overlap weighting analysis (RR 0.88, 95% CI: 0.65\u20131.21). Secondary efficacy and safety outcomes also showed no statistically significant between-group differences. Subgroup analyses suggested potential treatment interactions with stroke severity and etiology. Argatroban tended to be associated with better outcomes in patients with mild stroke severity after END, whereas tirofiban appeared to be associated with more favorable outcomes in patients with large-artery atherosclerosis and those with moderate-to-severe stroke severity after END.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>No statistically significant differences were detected in overall efficacy or safety outcomes between argatroban and tirofiban in patients with END after atherosclerosis-related ischemic stroke. Subgroup findings suggest that treatment effects may vary according to stroke subtype, highlighting the need for further prospective studies to explore mechanism-based, individualized antithrombotic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1896076","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:41:00Z","timestamp":1786426860000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of clinical efficacy between argatroban and tirofiban in patients with atherosclerotic cerebral infarction complicated by early neurological deterioration"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaolan","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Neurology, Tianxiang East Hospital","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianxiang East Hospital","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Dongyang Hospital of Wenzhou Medical University","place":["Dongyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangzhuang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Dongyang Hospital of Wenzhou Medical University","place":["Dongyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Affiliated Dongyang Hospital of Wenzhou Medical University","place":["Dongyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.str.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1007\/s12975-025-01357-x","article-title":"Exploring the efficacy and safety of Argatroban as an adjunct to antiplatelet therapy in ischemic stroke patients: a systematic review and meta-analysis","volume":"16","author":"Ahmed","year":"2025","journal-title":"Transl. Stroke Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1161\/STROKEAHA.110.595256","article-title":"Collateral flow predicts response to endovascular therapy for acute ischemic stroke","volume":"42","author":"Bang","year":"2011","journal-title":"Stroke"},{"key":"B4","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1161\/01.str.20.7.864","article-title":"Measurements of acute cerebral infarction: a clinical examination scale","volume":"20","author":"Brott","year":"1989","journal-title":"Stroke"},{"key":"B5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1517\/14656566.1.3.419","article-title":"Platelet glycoprotein IIb\/IIIa receptor antagonists","volume":"1","author":"Casserly","year":"2000","journal-title":"Expert Opin. Pharmacother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1001\/jama.2023.0550","article-title":"Effect of argatroban plus intravenous alteplase vs intravenous alteplase alone on neurologic function in patients with acute ischemic stroke: the ARAIS randomized clinical trial","volume":"329","author":"Chen","year":"2023","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1161\/STROKEAHA.123.043630","article-title":"Epidemiology, pathophysiology, and imaging of atherosclerotic intracranial disease","volume":"55","author":"Chen","year":"2024","journal-title":"Stroke"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e00382","DOI":"10.1016\/j.neurot.2024.e00382","article-title":"Baseline neurological deficit and argatroban plus alteplase in acute ischemic stroke: a post hoc analysis of ARAIS trial","volume":"21","author":"Cui","year":"2024","journal-title":"Neurotherapeutics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4103\/bc.bc_56_22","article-title":"Branch atheromatous disease and treatment","volume":"8","author":"Duan","year":"2022","journal-title":"Brain Circ."},{"key":"B10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1358\/dot.2006.42.4.953588","article-title":"Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions","volume":"42","author":"Escolar","year":"2006","journal-title":"Drugs Today (Barc)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5853\/jos.2025.05120","article-title":"Mechanism-oriented treatment of early neurologic deterioration in acute Ischemic stroke","volume":"28","author":"Heo","year":"2026","journal-title":"J. Stroke"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(13)70195-9","article-title":"Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment","volume":"12","author":"Holmstedt","year":"2013","journal-title":"Lancet Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000069105","article-title":"Development of argatroban as an anticoagulant and antithrombin agent in Japan","volume":"32","author":"Ikoma","year":"2002","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"B14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1586\/ehm.10.53","article-title":"Pharmacology of argatroban","volume":"3","author":"Jeske","year":"2010","journal-title":"Expert Rev. Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s40265-025-02222-9","article-title":"Tirofiban in acute ischemic stroke: mechanistic rationale, clinical advances, and emerging therapeutic strategies","volume":"85","author":"Jiang","year":"2025","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e47760","DOI":"10.1097\/MD.0000000000047760","article-title":"Real-world functional outcomes of sovateltide as an adjunct to standard therapy in acute ischemic stroke: a prospective observational study","volume":"105","author":"Kandasamy","year":"2026","journal-title":"Med. Baltim."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/STROKEAHA.124.047688","article-title":"Clinical and prognostic characteristics of acute BAD-related stroke: a multicenter MRI-based prospective study","volume":"55","author":"Li","year":"2024","journal-title":"Stroke"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17562864221147743","DOI":"10.1177\/17562864221147743","article-title":"Early neurological deterioration in patients with acute ischemic stroke: a prospective multicenter cohort study","volume":"16","author":"Liu","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/17474930221144911","article-title":"Cerebral small vessel disease: recent advances and future directions","volume":"18","author":"Markus","year":"2023","journal-title":"Int. J. Stroke"},{"key":"B29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1055\/s-2007-996129","article-title":"Development of argatroban, a direct thrombin inhibitor, and its clinical application","volume":"23","author":"Matsuo","year":"1997","journal-title":"Seminars Thrombosis Hemostasis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2165\/00003495-199856060-00017","article-title":"Tirofiban. A review of its use in acute coronary syndromes","volume":"56","author":"McClellan","year":"1998","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.3390\/ijms23063146","article-title":"Sovateltide mediated endothelin B receptors agonism and curbing neurological disorders","volume":"23","author":"Ranjan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/jama.2022.12584","article-title":"Effect of intravenous tirofiban vs placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke: the RESCUE BT randomized clinical trial","volume":"328","author":"Qiu","year":"2022","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e214228","DOI":"10.1212\/WNL.0000000000214228","article-title":"Thrombolysis alone vs with argatroban or eptifibatide: a prespecified subgroup analysis of the MOST trial","volume":"105","author":"Roy","year":"2025","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"aakag004","DOI":"10.1093\/esj\/aakag004","article-title":"2025 update to european stroke organisation (ESO) guideline on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage","volume":"11","author":"Sandset","year":"2026","journal-title":"Eur. Stroke J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1996","DOI":"10.1212\/WNL.0000000000207194","article-title":"Association of tirofiban with functional outcomes after thrombectomy in acute ischemic stroke due to intracranial atherosclerotic disease","volume":"100","author":"Sang","year":"2023","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00415-017-8490-3","article-title":"Revisiting \u2018progressive stroke\u2019: incidence, predictors, pathophysiology, and management of unexplained early neurological deterioration following acute ischemic stroke","volume":"265","author":"Seners","year":"2018","journal-title":"J. Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/jnnp-2014-308327","article-title":"Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications","volume":"86","author":"Seners","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1161\/STROKEAHA.116.015414","article-title":"Is unexplained early neurological deterioration after intravenous thrombolysis associated with thrombus extension?","volume":"48","author":"Seners","year":"2017","journal-title":"Stroke"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2503678","article-title":"Early tirofiban infusion after intravenous thrombolysis for stroke","volume":"393","author":"Tao","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","article-title":"Interobserver agreement for the assessment of handicap in stroke patients","volume":"19","author":"van Swieten","year":"1988","journal-title":"Stroke"},{"key":"B32","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1177\/23969873251319151","article-title":"Effects of tirofiban in preventing neurological deterioration in acute ischemic stroke with intracranial artery stenosis: a post hoc analysis of the TREND trial","volume":"10","author":"Wang","year":"2025","journal-title":"Eur. Stroke J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/23969873231219416","article-title":"European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke","volume":"9","author":"Wardlaw","year":"2024","journal-title":"Eur. Stroke J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/17474930241273685","article-title":"Early neurological deterioration in acute lacunar ischemic stroke: systematic review of incidence, mechanisms, and prospects for treatment","volume":"20","author":"Werring","year":"2025","journal-title":"Int. J. Stroke"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1161\/STROKEAHA.119.026240","article-title":"Low-dose tirofiban treatment improves neurological deterioration outcome after intravenous thrombolysis","volume":"50","author":"Wu","year":"2019","journal-title":"Stroke"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1470373","DOI":"10.3389\/fphar.2025.1470373","article-title":"Argatroban in patients with acute ischemic stroke with early neurological deterioration: a cost-effectiveness analysis from the perspective of Chinese healthcare system","volume":"16","author":"Xie","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1161\/STROKEAHA.121.036356","article-title":"Dual antiplatelet therapy plus argatroban prevents early neurological deterioration in branch atherosclerosis disease","volume":"53","author":"Xu","year":"2022","journal-title":"Stroke"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1161\/STROKEAHA.124.048872","article-title":"Effect of argatroban plus dual antiplatelet in branch atherosclerosis disease: a randomized clinical trial","volume":"56","author":"Xu","year":"2025","journal-title":"Stroke"},{"key":"B39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1001\/jamaneurol.2023.5093","article-title":"Argatroban in patients with acute ischemic stroke with early neurological deterioration: a randomized clinical trial","volume":"81","author":"Zhang","year":"2024","journal-title":"JAMA Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1001\/jamaneurol.2024.0868","article-title":"Effects of tirofiban on neurological deterioration in patients with acute ischemic stroke: a randomized clinical trial","volume":"81","author":"Zhao","year":"2024","journal-title":"JAMA Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1450156","DOI":"10.3389\/fneur.2024.1450156","article-title":"Intra-arterial cocktail therapy for patients with anterior circulation large vessel occlusion who achieved endovascular reperfusion","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa2214299","article-title":"Tirofiban for stroke without large or medium-sized vessel occlusion","volume":"388","author":"Zi","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1896076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:41:01Z","timestamp":1786426861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1896076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":42,"alternative-id":["10.3389\/fphar.2026.1896076"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1896076","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1896076"}}